Michelle L. Basil
Partner, Emerging Companies and Life Sciences Groups | Nutter McClennen & Fish LLP
Michelle Basil is a partner in the Business Department whose practice focuses on corporate and securities law, including venture capital transactions, public securities offerings, mergers and acquisitions, and strategic partnerships and collaborations as well as corporate governance and equity compensation matters. Michelle represents clients in a broad range of industries, including public and private life sciences, high technology and financial services companies. Michelle serves as outside general counsel to companies in biotechnology, medical devices, diagnostics, and health care services. Michelle received her B.A. and J.D. from the University of California, Berkeley.
Bruce L. Booth, D.Phil.
Partner, Life Sciences Group | Atlas Venture
Bruce Booth focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies. He currently sits on the Boards of Avila, Bicycle, Miragen, Nimbus, OnQity, ProtAffin and Zafgen. He also works or has worked closely with ARCA Biopharma (NASDAQ:ABIO), Archemix, NxStage Medical (NASDAQ:NXTM), Prestwick (sold to Biovail), Proprius (sold to Cypress), and Stromedix. Previously, Bruce was an investor with Caxton Health Holdings, and before that he was a consultant with McKinsey & Company on pharmaceutical R&D issues. Bruce serves as a Trustee of the New York Academy of Medicine and a member of the UCB Pharma Scientific Advisory Board. As a British Marshall Scholar, Bruce earned a Doctorate in Immunology from Oxford University, and received his B.S. summa cum laude in Biochemistry from Pennsylvania State University. He also writes a blog on venture capital and life science topics (www.lifescivc.com), and can be followed on Twitter@LifeSciVC. Bruce lives in Wellesley, MA with his wife and three wonderful kids.
Maria D. Buckley
Of Counsel, Life Sciences Group | Nutter McClennen & Fish LLP
Maria Buckley is Of Counsel in the Business Department and a member of the Life Sciences and Government Investigations & White Collar Criminal Defense practice groups. Maria has an extensive background in health law, with particular emphasis on contracts, reimbursement, regulatory interpretation and compliance. Her clients include hospitals, physician practices, ancillary services providers, HMOs, medical device companies, pharmaceutical companies and biotechnology companies. She advises companies, institutions and investigators in all phases of research, from the bench through product launch, including helping to document the clinical trials process. Maria regularly provides compliance advice and training with respect to pharmaceutical and medical device sales, marketing, pricing, manufacturing, and related commercialization activities. Maria is co-chair of MassBio’s Law and Policy Committee. Maria received a J.D. from Suffolk University Law School, and a B.S. from Boston University.
Stephen DeMarco Assurance
Partner, Health Industries Practice | PwC
Stephen DeMarco has over 21 years of experience working with venture-backed start-ups as well as large, multinational public life science and technology companies. Stephen has significant experience in assisting his medical device and biotech clients with the financial and business issues they face throughout their rapid growth cycles and serves his clients with proactive advice and consultation. Stephen has in-depth experience working on many complex client business issues including licensing and collaboration arrangements, inventory valuation, stock-based compensation, common stock valuation, revenue recognition, private equity and debt financing, initial public offerings as well as mergers and acquisitions. Stephen also leads PwC’s initiatives in working with venture-backed life sciences companies from its Entrepreneurial Services Center in Cambridge. His representative client experience includes Alere, IDEXX Labs, Cubist Pharmaceuticals, Curis, Anika Therapeutics, Metabolix, Salient Surgical Technologies, Aileron Therapeutics, Intrinsic Therapeutics, Ocular Therapeutics, Synageva BioPharma, and Proteostasis Therapeutics.
Michelle Dipp, M.D., Ph.D.
Founder and Partner | Longwood Founders Fund
Dr. Michell Dipp is the founding Chief Executive Officer of OvaScience and serves on the company’s Board of Directors. Dr. Dipp is also a Founder and Partner of Longwood Founders Fund, which founds and invests in biotechnology companies such as Alnara (acquired by Eli Lilly in 2010) and Verastem. Previously, Dr. Dipp was the Senior Vice President and Head of the CEEDD at GlaxoSmithKline. Prior to that, she was Vice President of Corporate Development at Sirtris (NASDAQ: SIRT, acquired by GlaxoSmithKline in 2008). Dr. Dipp led the successful acquisition of Sirtris by GSK in June 2008 for $720 million. Before joining Sirtris as a founding employee, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Beth Israel Deaconess Medical Center Board of Overseers and the Board of Directors of the City on a Hill Charter School in Roxbury, Mass. Dr. Dipp holds an M.D. and a Ph.D. from the University of Oxford.
Brian M. Gallagher, Jr., Ph.D.
Partner | SR One Ltd.
Brian Gallagher joined SR One in 2010 and set up the Boston office. He is currently a member of the Board of Directors of Aileron Therapeutics and SpringLeaf Therapeutics, and is an observer on the Boards of Constellation Pharmaceuticals and Dicerna Pharmaceuticals. Brian has nearly 15 years of business development, operational and R&D experience in both biotech and large pharma companies. He most recently led corporate development and business operations at Sirtris Pharmaceuticals, which was acquired by GSK in 2008. Prior to Sirtris, he was with Alantos Pharmaceuticals (acquired by Amgen), and he began his career in R&D at the Japanese pharma Eisai, where he initiated and led multiple programs and scientific teams. Brian received his M.S. and Ph.D. degrees in Organic Chemistry from The University of Michigan, and a B.S. in Chemistry from The University of Massachusetts, where he was awarded a full scholarship.
President and Chief Executive Officer | Solace Therapeutics
Bill Gruber is currently the President and CEO of Solace Therapeutics, a startup company in the female urinary incontinence field. Bill was the President and CEO of Interlace Medical which he founded in August 2006. While at Interlace he raised over $28M in venture capital for the development and launch of devices for the treatment of abnormal uterine bleeding caused by fibroids. The company was purchased by Hologic in 2011 for $125M. Bill has extensive experience in organizational development and in product development for rapid growth businesses. Prior to joining Interlace Medical, he was President of Hemedex, Inc. where he led fundraising efforts and developed the company’s business plan. Prior to joining Hemedex, Bill spent five years at Cortek Inc., a spinal products company. As Cortek’s V.P. of Sales and Marketing, he built sales from $612K to over $10M. During his last two years he was the V.P. of New Business Development and Marketing. In this role he was instrumental in creating Soteira, a Cortek subsidiary, focused on devices for treating vertebral compression fractures. Prior to Cortek, Bill spent ten years at Boston Scientific Corporation. Before leaving Boston Scientific Corporation, he held the position of Director of the $172M Global Atherosclerotic Therapy business. Prior to entering the medical device sector, Bill spent five years in sales and marketing roles at Procter & Gamble.
Chief Executive Officer | Halloran Consulting Group
Throughout her 24 years in the pharmaceutical and biotechnology industry, Laurie Halloran has demonstrated her commitment to improving the organizational effectiveness of clinical research programs. Optimizing the execution of clinical research programs requires a depth and breadth of experience not commonly found in the industry today. Laurie’s major accomplishments reflect her contributions and expertise throughout the multiple phases of the drug development process. Some of her accomplishments include leading clinical development in several biopharmaceutical companies from IND through late stage clinical trials, and reorganizing dozens of biopharma clinical research departments to optimize organizational efficiency. Laurie was recognized in 2010 by Pharmavoice as one of the 100 most inspiring individuals. She is well known as an industry expert – speaking, publishing and training throughout the world on best practices. She obtained her BSN from Russell Sage College and her MS from Lesley University and is on the faculty of Boston University Medical School.
Donald D. Haut, Jr., Ph.D.
Senior Vice President for Strategy & Business Development | Smith & Nephew
Don Haut, Ph.D. is the Senior Vice President for Business Development & Strategy at Smith & Nephew Advanced Surgical Devices Division, a leader in products for Orthopedic Surgery, and Sports Medicine. In this role he is responsible for development of long-term business strategy for the Division, and all business development activities. He is also responsible for emerging business including Women’s Health, Veterinary Medicine, and Patient Positioning businesses. Immediately prior to joining Smith & Nephew, Don was Director of Strategy and Business Development for 3M’s Safety, Security and Protection Services Business Group. He has also been a Partner with JSB Partners, a boutique investment bank and financial advisor, and a consultant with McKinsey & Company. Don holds an MBA from the Olin School at Washington University in St. Louis; and a Ph.D. in Molecular Biology from the University of Missouri-Columbia School of Medicine.
Julius (Jay) Knowles, MS, MBA
Head, Platforms, Strategic Alliances | Novartis Institutes for BioMedical Research
Julius (Jay) Knowles is Head, Platforms, Strategic Alliances for Novartis, responsible for creating technology-based and drug discovery collaborations. Previously, Mr. Knowles was founder and President of Novalar Pharmaceuticals, a specialty pharmaceutical company that recently launched their first drug. Prior to this, he was Vice President, Business Development, at Structural Genomix, and Director, Research and Development Planning at Vertex Pharmaceuticals. He has an MBA in Finance from Wharton Business School, and an M.Sc. from UC Berkeley in Chemistry.
Gregory L. Miller
Head of Business and Corporate Development | Concert Pharmaceuticals, Inc.
Greg Miller currently serves as Head of Business and Corporate Development at Concert Pharmaceuticals, a company that applies precision deuterium chemistry to create differentiated New Chemical Entities (NCEs). Prior to joining Concert, he was Senior Director, Business Development and Corporate Strategy at AMAG Pharmaceuticals. Prior to joining AMAG, Mr. Miller held a variety of analytical and leadership roles in the Corporate Development group at Genzyme Corporation. Mr. Miller also held positions focused on epidemiology and clinical research before joining the biotechnology industry. He received a BA in Psychology from Brandeis University, conducted a Harris Fellowship in Developmental Psychology at Yale University, received a Master of Public Health in Epidemiology and Biostatistics at Boston University and an MBA from Boston University.
Patrice M. Milos, Ph.D.
Site Head | Pfizer, Centers for Therapeutic Innovation, Boston
Dr. Patrice Milos recently returned to Pfizer taking on a new role as Boston Site Head for the Centers for Therapeutic Innovation. The CTI model brings a new and exciting approach through the establishment of academic medical center partnerships with Pfizer to establish proof of mechanism for novel targets and pathways to treat human disease. Dr. Milos previously served as the Senior Vice President and Chief Scientific Officer for Helicos BioSciences Corporation, Cambridge, MA joining in June 2007. Her expertise and extensive knowledge in the life sciences helped advance the company’s efforts to develop and apply innovative and breakthrough single molecule DNA and RNA sequencing technology with recent focus on molecular diagnostics. Accomplishments included the development of the world’s first and only method for direct capture and sequencing of BRCA1/2, the only method for direct sequencing of RNA as well as the establishment of collaborations with world class institutions including the Broad Institute, Harvard Medical School, Massachusetts General Hospital and the Children’s Oncology Group. Dr. Milos has previously served as Executive Director for Pfizer Global Research and Development. Dr. Milos was responsible for leadership, strategy alignment and execution of the scientific disciplines of pharmacogenomics, proteomics, metabonomics and RNA profiling across the Pfizer portfolio from early discovery into the marketplace. Initially joining Pfizer in 1993, Dr. Milos held numerous research positions of increasing responsibility focusing on Cardiovascular and Metabolic Disease, Pharmacogenomics, DNA Sequencing, Biomarkers and Molecular Sciences. Dr. Milos recently served on the National Advisory Council for Human Genome Research and was pivotal in the establishment and oversight of key Pfizer strategic investments in the genomics area, most notably, the Genetic Association Information Network in partnership with NIH. She also sits on several journal editorial boards and has published and presented extensively in genomic sciences. Dr. Milos conducted post-doctoral fellowships at Brown University and Harvard University. She earned her M.S. and Ph.D. degrees at Rensselaer Polytechnic Institute in Troy, NY.